Patents by Inventor Brian D. Lichty
Brian D. Lichty has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8282917Abstract: The present invention provides mutant viruses with a decreased ability to block nuclear transport of mRNA or protein in an infected cell which are attenuated in vivo. The mutant viruses of the present invention may also be capable of triggering the anti-viral systems of normal host cells while remaining sensitive to the effects of these systems. The present invention further provides for the use of the mutant viruses in a range of applications including, but not limited to, as therapeutics for the treatment of cancer and infections, as vaccines and adjuvants, as viral vectors, and as oncolytic and cytolytic agents for the selective lysis of malignant or infected cells.Type: GrantFiled: March 30, 2010Date of Patent: October 9, 2012Assignees: Wellstat Biologics Corporation, Ottawa Hospital Research InstituteInventors: John C. Bell, Brian D. Lichty, David F. Stodjl
-
Patent number: 8147822Abstract: The present invention is directed to a method of reducing the viability of a tumor cell involving administering a virus that is not a common human pathogen to the tumor cell. Preferably, the virus exhibits differential susceptibility, in that normal cells are not affected by the virus. This differential susceptibility is more pronounced in the presence of interferon. The tumor cell is characterized by having low levels, or no, PKR activity, or as being PKR?/?, STAT1?/? or both PKR?/? and STAT1?/?. The virus is selected from the group consisting of Rhabdovirus and picornavirus, and preferably is vesicular stomatitis virus (VSV) or a derivative thereof.Type: GrantFiled: September 18, 2000Date of Patent: April 3, 2012Assignee: Wellstat Biologics CorporationInventors: John C. Bell, Nahum Sonenberg, David F. Stojdl, Earl G. Brown, Harold L. Atkins, Ricardo M. Marius, Brian D. Lichty, Shane B. Knowles
-
Publication number: 20100272687Abstract: The present invention provides mutant viruses with a decreased ability to block nuclear transport of mRNA or protein in an infected cell which are attenuated in vivo. The mutant viruses of the present invention may also be capable of triggering the anti-viral systems of normal host cells while remaining sensitive to the effects of these systems. The present invention further provides for the use of the mutant viruses in a range of applications including, but not limited to, as therapeutics for the treatment of cancer and infections, as vaccines and adjuvants, as viral vectors, and as oncolytic and cytolytic agents for the selective lysis of malignant or infected cells.Type: ApplicationFiled: March 30, 2010Publication date: October 28, 2010Inventors: John C. Bell, Brian D. Lichty, David F. Stojdl
-
Patent number: 7731974Abstract: The present invention provides mutant viruses with a decreased ability to block nuclear transport of mRNA or protein in an infected cell which are attenuated in vivo. The mutant viruses of the present invention may also be capable of triggering the anti-viral systems of normal host cells while remaining sensitive to the effects of these systems. The present invention further provides for the use of the mutant viruses in a range of applications including, but not limited to, as therapeutics for the treatment of cancer and infections, as vaccines and adjuvants, as viral vectors, and as oncolytic and cytolytic agents for the selective lysis of malignant or infected cells.Type: GrantFiled: March 29, 2004Date of Patent: June 8, 2010Assignees: Ottawa Hospital Research Institute, Wellstat Biologics CorporationInventors: John C. Bell, Brian D. Lichty, David F. Stojdl
-
Patent number: 7192580Abstract: The subject invention relates to viruses that are able to purge (reduce or eliminate) undesirable cells in a mixture of cells. Undesirable cells can include neoplastic cells, cells mediating graft-versus host diseases, and autoimmune cells. The subject invention also relates to the purging of undesirable cells from bone marrow or peripheral blood cell harvests in the treatment of mammals including cancer patients, transplant recipients, and patients with autoimmune disease.Type: GrantFiled: November 19, 2003Date of Patent: March 20, 2007Assignees: Wellstat Biologics Corporation, University of OttawaInventors: Harold L. Atkins, John C. Bell, Conrad J. Heilman, Jr., Brian D. Lichty, Robert M. Lorence, Michael S. Roberts, David F. Stojdl
-
Publication number: 20040208849Abstract: The present invention is directed to a method of reducing the viability of a tumor cell involving administering a virus that is not a common human pathogen to the tumor cell. Preferably, the virus exhibits differential susceptibility, in that normal cells are not affected by the virus. This differential susceptibility is more pronounced in the presence of interferon. The tumor cell is characterized by having low levels, or no, PKR activity, or as being PKR−/−, STAT1−/− or both PKR−/− and STAT1−/−. The virus is selected from the group consisting of Rhabdovirus and picomavirus, and preferably is vesicular stomatitis virus (VSV) or a derivative thereof.Type: ApplicationFiled: December 22, 2003Publication date: October 21, 2004Inventors: John C. Bell, Nahum Sonenberg, David F. Stojdl, Earl G. Brown, Harold L. Atkins, Ricardo M. Marius, Brian D. Lichty, Shane B. Knowles
-
Publication number: 20040170607Abstract: The present invention is directed to a method of reducing the viability of a tumor cell involving administering a virus that is not a common human pathogen to the tumor cell. Preferably, the virus exhibits differential susceptibility, in that normal cells are not affected by the virus. This differential susceptibility is more pronounced in the presence of interferon. The tumor cell is characterized by having low levels, or no, PKR activity, or as being PKR−/−, STAT1−/− or both PKR−/− and STAT1−/−. The virus is selected from the group consisting of Rhabdovirus and picornavirus, and preferably is vesicular stomatitis virus (VSV) or a derivative thereof.Type: ApplicationFiled: December 23, 2003Publication date: September 2, 2004Inventors: John C. Bell, Nahum Sonenberg, David F. Stojdl, Earl G. Brown, Harold L. Atkins, Ricardo M. Marius, Brian D. Lichty, Shane B. Knowles
-
Publication number: 20040109878Abstract: The subject invention relates to viruses that are able to purge (reduce or eliminate) undesirable cells in a mixture of cells. Undesirable cells can include neoplastic cells, cells mediating graft-versus host diseases, and autoimmune cells. The subject invention also relates to the purging of undesirable cells from bone marrow or peripheral blood cell harvests in the treatment of mammals including cancer patients, transplant recipients, and patients with autoimmune disease.Type: ApplicationFiled: November 19, 2003Publication date: June 10, 2004Inventors: Harold L. Atkins, John C. Bell, Conrad J. Heilman, Brian D. Lichty, Robert M. Lorence, Michael S. Roberts, David F. Stojdl
-
Publication number: 20020037543Abstract: The subject invention relates to viruses that are able to purge (reduce or eliminate) undesirable cells in a mixture of cells. Undesirable cells can include neoplastic cells, cells mediating graft-versus host diseases, and autoimmune cells. The subject invention also relates to the purging of undesirable cells from bone marrow or peripheral blood cell harvests in the treatment of mammals including cancer patients, transplant recipients, and patients with autoimmune disease.Type: ApplicationFiled: June 26, 2001Publication date: March 28, 2002Inventors: Harold L. Atkins, John C. Bell, Conrad J. Heilman, Brian D. Lichty, Robert M. Lorence, Michael S. Roberts, David F. Stojdl